Doctor profile · Federal record
Dr. Mark Karides, MD
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Chicago, IL
- NPI 1932206307
- Accepts Medicare
- MIPS 66.3 / 100 · 2023
- 38 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
7447 W Talcott Ave, Suite One
Chicago, IL 606313745
(773) 774-0042
fax (773) 774-2008
Credentials & registration
- NPI registered
- September 2006 — 20 yrs on file
- Profile last updated
- December 17, 2021
- Year of graduation
- 1988 — 38 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Illinois #036081870
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1932206307. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
161,389
Distinct HCPCS
10
Medicare allowed
$1,866,175
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q5110 |
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 50,400 | 17 | $0 | |
J1453 |
Injection, fosaprepitant, 1 mg | 27,300 | 38 | $0 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 24,500 | 14 | $0 | |
J9271 |
Injection, pembrolizumab, 1 mg | 16,000 | 15 | $54 | |
J0897 |
Injection, denosumab, 1 mg | 8,580 | 19 | $23 | |
J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 7,660 | 13 | $3 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 4,020 | 64 | $0 | |
J1437 |
Injection, ferric derisomaltose, 10 mg | 4,000 | 29 | $20 | |
Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 3,560 | 14 | $8 | |
J2405 |
Injection, ondansetron hydrochloride, per 1 mg | 2,906 | 34 | $0 |
In context: peer comparison
Among 77 peers in this city , average services per provider: 870. This provider delivers 186× the peer median.Open Payments
Industry payments received
All-time total
$2,807
Transactions
100
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 31 | $494.53 | |
| Celgene Corporation | 11 | $326.05 | |
| E.R. Squibb & Sons, L.L.C. | 11 | $318.57 | |
| PFIZER INC. | 11 | $238.44 | |
| BeiGene USA, Inc. | 2 | $170.85 | |
| ABBVIE INC. | 9 | $159.19 | |
| Astellas Pharma US Inc | 4 | $98.58 | |
| AstraZeneca Pharmaceuticals LP | 4 | $90.19 | |
| Pharmacosmos Therapeutics Inc. | 3 | $71.41 | |
| Gilead Sciences, Inc. | 3 | $70.94 | |
| Merck Sharp & Dohme LLC | 3 | $67.32 | |
| GlaxoSmithKline, LLC. | 2 | $57.04 | |
| Incyte Corporation | 2 | $55.46 | |
| Daiichi Sankyo Inc. | 2 | $52.27 | |
| Eisai Inc. | 2 | $49.10 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
609
Patients
128
Total drug cost
$2,576,892
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 70 | 20 | $1,900 |
| Revlimid (Lenalidomide) | Brand | 70 | 12 | $1,295,031 |
| Prednisone | Generic | 69 | 16 | $701 |
| Dexamethasone | Generic | 60 | 25 | $1,405 |
| Ondansetron Odt (Ondansetron) | Brand | 46 | 29 | $1,123 |
| Abiraterone Acetate | Generic | 41 | 0 | $70,373 |
| Hydroxyurea | Generic | 38 | 11 | $2,160 |
| Anastrozole | Generic | 32 | 0 | $1,152 |
| Venclexta (Venetoclax) | Brand | 31 | 0 | $433,055 |
| Warfarin Sodium | Generic | 30 | 0 | $522 |
Hospital affiliations
Frequently asked questions
What is Dr. Mark Karides's medical specialty?
Dr. Mark Karides practices Hematology & Oncology Physician in Chicago, IL.
Where does Dr. Mark Karides practice?
Dr. Mark Karides practices at 7447 W Talcott Ave, Chicago, IL 606313745. Office phone: 7737740042.
What is Dr. Mark Karides's NPI?
Dr. Mark Karides's National Provider Identifier (NPI) is 1932206307, issued by NPPES.
Does Dr. Mark Karides accept Medicare assignment?
Yes. Dr. Mark Karides accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Mark Karides commonly perform?
Top Medicare-reported procedures in 2023: Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS Q5110); Injection, fosaprepitant, 1 mg (HCPCS J1453); Injection, oxaliplatin, 0.5 mg (HCPCS J9263). Source: CMS Medicare Physician & Other Practitioners file.